![](https://www.albimmune.com/wp-content/uploads/2022/11/alliance-logo-1551x579-1-300x112.png)
About
Human albumin to treat B cell dysfunction in decompensated cirrhosis and sepsis. An investigation to assess dosage, biomarkers of immune response, and further insights on pathophysiology.
- Open label, randomized clinical trial
- 150 patients
- 11 sites
![](https://www.albimmune.com/wp-content/uploads/2022/12/alliance-description-954x1024.png)
Description
To assess the dose effect of albumin treatment on B cell and neutrophil function in three groups of subjects:
![](https://www.albimmune.com/wp-content/uploads/2022/12/icon-healthy-subject-150x150.png)
Healthy subjects
![](https://www.albimmune.com/wp-content/uploads/2022/12/icon-cirrhosis-150x150.png)
Patients with decompensated cirrhossis without indication for albumin therapy
![](https://www.albimmune.com/wp-content/uploads/2022/12/icon-sepsis-150x150.png)
Non-cirrhotic patients hospitalized with sepsis
Centers
![](https://www.albimmune.com/wp-content/uploads/2022/12/alliance-centers-2048x1621.png)
Barcelona, Spain
- Hospital Clínic de Barcelona
- Hospital de la Santa Creu i Sant Pau
- Hospital del Mar
- Hospital Germans Trias i Pujol
- Hospital Universitari Vall d’Hebron
Madrid, Spain
- Hospital Gregorio Marañón
- Hospital Universitario Ramón y Cajal
Sabadell, Spain
- Hospital Universitari Parc Taulí de Sabadell
Brussels, Belgium
- CUB Hôpital Erasme
Münster, Germany
- Uniklinik Münster
Padua, Italy
- Azienda Ospedale Università Padova